ArticleIn vivo (Athens, Greece)
Bilateral Venous Access for Cardiac Resynchronization Therapy in a Hemodialysis Patient With Cabozantinib-associated Heart Failure.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative Cross-platform Analysis of Kinase Inhibitor Effects on Statin-relevant Cardioprotective Pathways in Human Cardiomyocytes.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCabozantinib, a multi-targeted tyrosine kinase inhibitor, is widely used for the treatment of renal and hepatic cancers. While cabozantinib-associated cardiotoxicity is rare, it has been documented in several cases. In most instances, cancer therapeutics-related cardiac dysfunction (CTRCD) is managed by discontinuing cabozantinib and initiating cardioprotective agents. In this report, we present the case of a 63-year-old male with cabozantinib-induced heart failure (HF) with reduced ejection fraction (EF) and complete left bundle branch block (CLBBB). CASE REPORT: The patient, undergoing hemodialysis for chronic kidney disease, had limited therapeutic options due to prior treatment failures. Despite six months of standard HF therapy, symptoms persisted, prompting cardiac resynchronization therapy (CRT) implantation without interrupting cabozantinib. Due to the presence of a dialysis shunt in the patient's left arm, the right subclavian vein was selected for venous access to minimize the risk of lead-related complications. Using a tunneling tool, the left ventricular lead was placed
conclusionThis case highlights the utility of bilateral venous access with a tunneling tool in cardiac resynchronization therapy, particularly for patients with hemodialysis shunts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.